Bakay, Marina
Pandey, Rahul
Grant, Struan F.A.
Hakonarson, Hakon
Article History
First Online: 4 November 2019
Compliance with Ethical Standards
:
: Marina Bakay and Rahul Pandey report they have a patent pending on new innovative weight reduction therapies targeting CLEC16A.Struan F.A. grant reports he has a patent issue on genetic alterations and methods of use thereof for the diagnosis and treatment of type I diabetes issued (patent number 10125395); a patent issued on genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes (patent number 10266896); and a patent issued on genetic alterations on chromosomes 21Q, 6Q, and 15Q and methods of use thereof for the diagnosis and treatment of type 1 diabetes (patent number 10066266).Hakon Hakonarson reports he has a patent issued on genetic alterations and methods of use thereof for the diagnosis and treatment of type I diabetes issued (patent number 10125395); a patent issued on genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes issued (patent number 10266896); a patent issued on genetic alterations on chromosomes 21Q, 6Q, and 15Q and methods of use thereof for the diagnosis and treatment of type 1 diabetes (patent number 10066266); and a patent pending on new innovative weight reduction therapies targeting CLEC16A.
: All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).